Covid 19 Research Clinical Trials by Shray Alag

Exposure

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (5)

	Name (Synonyms)	Correlation
drug2370	Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki	0.71
drug1871	IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki	0.71
drug3781	Sterile Normal Saline for Intravenous Use Wiki	0.71

	Name (Synonyms)	Correlation
drug871	Centricyte 1000 Wiki	0.71
drug2127	Liberase Enzyme (Roche) Wiki	0.71

Correlated MeSH Terms (10)

	Name (Synonyms)	Correlation
D011649	Pulmonary Alveolar Proteinosis NIH	0.71
D054990	Idiopathic Pulmonary Fibrosis NIH	0.41
D017563	Lung Diseases, Interstitial NIH	0.19

	Name (Synonyms)	Correlation
D011658	Pulmonary Fibrosis NIH	0.18
D008171	Lung Diseases, NIH	0.14
D011024	Pneumonia, Viral NIH	0.08
D007239	Infection NIH	0.07
D003141	Communicable Diseases NIH	0.05
D045169	Severe Acute Respiratory Syndrome NIH	0.03
D018352	Coronavirus Infections NIH	0.03

Correlated HPO Terms (4)

	Name (Synonyms)	Correlation
HP:0006517	Intraalveolar phospholipid accumulation HPO	0.71
HP:0006515	Interstitial pneumonitis HPO	0.19
HP:0002206	Pulmonary fibrosis HPO	0.18

	Name (Synonyms)	Correlation
HP:0002088	Abnormal lung morphology HPO	0.14

Clinical Trials

Navigate: Correlations HPO

There are 2 clinical trials

1 Gut Microbiota, "Spark and Flame" of COVID-19 Disease

Elderly, hypertension, diabetes and cardiovascular diseases are risk factors for COVID-19 morbility and mortality. However, the real reason for this is not yet understood. It is well documented that gut microbiota has a critical role in health, particularly in the immune system and therefore, we propose that gut microbiota composition could affect vulnerability and disease outcomes of COVID-19.

NCT04355741

Conditions

COVID-19

Interventions

Other: Exposure

Primary Outcomes

Measure: Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.

Time: Stool samples of COVID-19 patients will be collected after subject enrollment (single point collection)

Secondary Outcomes

Measure: Differences in gut microbiota composition between COVID-19 patients in relation to mortality.

Time: Through study completion, an average of 3 months.

Measure: Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.

Time: Through study completion, an average of 3 months.

Measure: Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.

Time: Through study completion, an average of 3 months.

2 VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity

Vitamin D deficiency has been linked to hypertension, autoimmune, infectious and cardiovascular diseases which are risk factors for COVID-19. Moreover, COVID-19 patients have a very high prevalence of hypovitaminosis D (Turin data). Taken together, we aim to investigate whether genetic variants in vitamin D-related genes contribute to a poor COVID-19 outcome, particularly in hypertension and CV patients, proposing thus a personalized therapeutics based on vitamin D supplementation in order to reduce the severity and deaths.

NCT04370808

Conditions

COVID-19

Interventions

Other: Exposure

MeSH:Infection

Primary Outcomes

Measure: Differences in vitamin D blood levels between COVID-19 patients with different degrees of disease severity.

Time: Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).

Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients with different degrees of disease severity.

Time: Blood samples of COVID-19 patients will be collected at baseline (after subject enrollment; single point collection).

Secondary Outcomes

Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to mortality.

Time: Through study completion, an average of 3 months.

Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to length of stay in hospitals.

Time: Through study completion, an average of 3 months.

Measure: Differences in vitamin D blood levels between COVID-19 patients in relation to duration of mechanical ventilation.

Time: Through study completion, an average of 3 months.

Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to mortality.

Time: Through study completion, an average of 3 months.

Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to length of stay in hospitals.

Time: Through study completion, an average of 1 year.

Measure: Differences in genetic variants in vitamin D-related genes between COVID-19 patients in relation to duration of mechanical ventilation.

Time: Through study completion, an average of 3 months.

No related HPO nodes (Using clinical trials)

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials

No related HPO nodes (Using clinical trials)

Reports

Data processed on September 26, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports MeSH Reports HPO Reports

CovidResearchTrials

Report Sections

See All Reports

Exposure

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (5)

Correlated MeSH Terms (10)

Correlated HPO Terms (4)

Clinical Trials

1 Gut Microbiota, "Spark and Flame" of COVID-19 Disease

NCT04355741

Conditions

Interventions

Primary Outcomes

Secondary Outcomes

2 VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity

NCT04370808

Conditions

Interventions

MeSH:Infection

Primary Outcomes

Secondary Outcomes

No related HPO nodes (Using clinical trials)

HPO

No related HPO nodes (Using clinical trials)

Reports

Interventions

MeSH

HPO

All Terms

Google Colab

Report Sections

See All Reports

Exposure

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (5)

Correlated MeSH Terms (10)

Correlated HPO Terms (4)

Clinical Trials

1 Gut Microbiota, "Spark and Flame" of COVID-19 Disease Click for details

NCT04355741

Conditions

Interventions

Primary Outcomes

Secondary Outcomes

2 VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity Click for details

NCT04370808

Conditions

Interventions

MeSH:Infection

Primary Outcomes

Secondary Outcomes

No related HPO nodes (Using clinical trials)

HPO

No related HPO nodes (Using clinical trials)

Reports

Interventions

MeSH

HPO

All Terms

Google Colab

1 Gut Microbiota, "Spark and Flame" of COVID-19 Disease

2 VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity